Exhibit 99.1 REGENERON Press Release Regeneron Reports Third Quarter 2024 Financial and Operating Results • Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 • Third quarter 2024 Dupixent global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 • Third quarter 2024 U.S. net sales for EYLEA HD and EYLEA increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD • Third quarter 2024 Libtayo global net s ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HDThird quarter 2024 Libtayo® global net sales increased 24% to $289 million versus third quarter 2023Third quarter 2024 GAAP diluted EPS increased 30% to ...

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report third-quarter results on Oct. 31, 2024. The Zacks Consensus Estimate for revenues is pegged at $3.67 billion, while the same for earnings is pinned at $11.75 per share. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. REGN Faces Decline in Eylea Sales, Dupixent Fuels Growth Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine. A significant chunk of Regeneron's rev ...

The biotech sector represents companies developing innovative treatments and therapies using biological processes. These firms range from early-stage research companies to established pharmaceutical developers. Biotech stocks offer investment opportunities in companies working on groundbreaking medical solutions. The sector spans various therapeutic areas, from cancer treatments to rare diseases. Investing in biotech stocks can provide exposure to potentially revolutionary medical breakthroughs. Successful ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wellcontrolled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the US suffer from chronic spontaneous urticaria ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the U.S. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the Phase 3 PHOTON trial presented at AAO Patients switched to EYLEA HD experienced substantially slower fluid reaccumulation, as compared to their previous rate of fluid reaccumulation with EYLEA® (aflibercept) Injection 2 mg The consistent achievement of much longer dosing intervals with EYLEA HD – together with ...

Regeneron (REGN) has been on a downward spiral lately with significant selling pressure. After declining 11.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed the S&P 500 Index.REGN Outperforms Industry & SectorImage Source: Zacks Investment ResearchRegeneron’s efforts to diversify its portfolio have impressed its investors, even as lead drug Eylea faces challenges.Regeneron’s EYLEA HD Stabilizes Ophthalmology UnitEylea is an anti-vascular endothelial growth fact ...

The biotech needs to overcome an issue most drugmakers face at some point.Biotech giant Regeneron Pharmaceuticals (REGN -0.17%) has performed pretty well this year and over the trailing-12-month period, thanks to solid financial results and exciting clinical and regulatory progress.However, the company has encountered some headwinds with one of its most important medicines, Eylea, which treats an eye disease called wet age-related macular degeneration (AMD). And recently, Regeneron got more bad news on the ...